title: [Intralymphatic chemotherapy with adriamycin-adsorbing nanometric activated carbon:pharmacokinetic experiment with dogs].
abstract: OBJECTIVE
  To observe the pharmacokinetics of adriamycin-adsorbing nanometric activated carbon in intralymphatic chemotherapy.
  
  
  METHODS
  Two ml of suspension of activated carbon with the diameter of 21 nm was mixed with adriamycin 5 mg. Eighteen dogs were randomly divided into 6 equal groups. The above mentioned mixture was injected subserosally to the anterior wall of gastric antrum of the dogs. Thirty minutes, 1 h, 2 h, 1 day, and 3 days after the injection the gastroepiploic lymph nodes of the Groups 1 - 5 were obtained. And Group 6 underwent extraction of venous blood samples 5, 15, 30, 60, 120, and 240 minutes after the injection and extraction of thoracic duct fluid 5, 15, 30, 60, 120, 240, and 360 minutes after the injection. The adriamycin concentrations at different time points were determined by mass spectrometer. The lymphatic vessels and nodes at the gastric wall were observed by the naked eyes.
  
  
  RESULTS
  Black tiny lymphatic vessels and lymph nodes were visualized around the injection areas immediately after the injection. Adriamycin content could be detected 30 min after the injection and lasted for 72 h at high levels with the peak content of (84.6 +/- 2.0) microg per gram tissue at 60 min in the perilymph node of gastroepiploic artery. The adriamycin concentration in the lymph fluid of thoracic duct reached the top level of 162.5 ng/ml 30 min after the injection, and then decreased slowly. Adriamycin could be still detected in lymph fluid 6 h after injection. No trace of adriamycin was found in the blood at any time points.
  
  
  CONCLUSIONS
  The content of adriamycin can keep high and last long in the drainage of lymph node and lymph fluid in the treatment of intralymphatic chemotherapy using adriamycin-adsorbing nanometric activated carbon.
authors.affiliation: Department of Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
authors.forename: Zheng-hao
authors.initials: ZH
authors.lastname: Hua
authors.forename: Song-yan
authors.initials: SY
authors.lastname: Cai
authors.forename: Guang-jian
authors.initials: GJ
authors.lastname: Huang
authors.forename: Chun-tao
authors.initials: CT
authors.lastname: Wu
authors.forename: Jun
authors.initials: J
authors.lastname: Gan
authors.forename: Cheng-en
authors.initials: CE
authors.lastname: Hu
authors.forename: Quan-xing
authors.initials: QX
authors.lastname: Ni
authors.forename: Yan-ling
authors.initials: YL
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D002606:Charcoal / Q000737:chemistry; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D016503:Drug Delivery Systems / Q000379:methods; D008198:Lymph Nodes / Q000378:metabolism*; D013058:Mass Spectrometry; D037742:Nanotubes, Carbon / Q000737:chemistry; D011897:Random Allocation
chemical_list: D000903:Antibiotics, Antineoplastic; D037742:Nanotubes, Carbon; D002606:Charcoal; D004317:Doxorubicin